Table 2 Clinical Characteristics.
Normal control (n = 19) | Takotsubo syndrome (n = 26) | Dilated cardiomyopathy (n = 26) | P-value | |
---|---|---|---|---|
Left ventriculography data | ||||
LVEDV (mL/m2)* | 72.8 ± 22.0 | 78.3 ± 17.1 | 122.0 ± 33.1 | <0.001 |
LVESV (mL/m2)* | 26.1 ± 10.3 | 41.3 ± 16.6 | 81.9 ± 27.0 | <0.001 |
LVEF (%) | 64.0 ± 9.4 | 47.8 ± 14.0 | 33.2 ± 8.9 | <0.001 |
Laboratory data on admission | ||||
Uric acid (mg/dL) | 6.4 ± 1.9 | 4.9 ± 1.3 | 7.0 ± 2.4 | 0.002 |
eGFR (mL/min/1.73 m2)† | 73.1 ± 24.7 | 74.3 ± 20.9 | 73.7 ± 25.4 | 0.72 |
Corrected serum calcium (mg/dL) | 9.4 ± 0.3 | 8.9 ± 0.4 | 9.2 ± 0.4 | 0.006 |
BNP (pg/mL) | 66.2 ± 8.4 | 489.7 ± 406.6 | 678.5 ± 932.4 | <0.001 |
PRA (ng/mL/hr) | 2.5 ± 2.8 | 3.2 ± 6.2 | 4.3 ± 6.8 | 0.29 |
PAC (pg/mL) | 154.5 ± 109.5 | 121.5 ± 127.6 | 145.1 ± 156.8 | 0.24 |
Plasma adrenaline (pg/mL)‡§ | n/a | 78.0 (38.0–268.7) | n/a | |
Plasma noradrenaline (pg/mL)‡¶ | n/a | 671.0 (265.5–1169.5) | n/a |